Research Progress of Antibody-Drug Conjugates for Endometrial Cancer

A narrative overview of recent advances in antibody-drug conjugates for treating endometrial cancer. The file, authored by Yuying Jiang, was last updated on April 27, 2026, and is shared under a CC-BY-4.0 license. Its content focuses on key therapeutic targets including Trop-2, HER2, FRα, and Nectin-4.

Use Cases

• Reviewing clinical trial efficacy for ADCs like Sacituzumab Govitecan and Trastuzumab Deruxtecan based on the description of objective response rates.
• Identifying promising molecular targets for endometrial cancer treatment based on the discussion of Trop-2, HER2, FRα, and Nectin-4.
• Analyzing combination therapy strategies based on the mention of ADCs paired with chemotherapy and immunotherapy.
• Assessing challenges in ADC development based on the described issues of resistance and safety.

Strengths

• Focuses on a specific and emerging area of oncology research: antibody-drug conjugates for endometrial cancer.
• Explicitly discusses four key molecular targets (Trop-2, HER2, FRα, Nectin-4) and named drug candidates.
• Has a clear, recent last-updated date of 2026-04-27.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 10.0 KB, suggesting limited scope or a summary document.

Provenance

Source

figshare, author Yuying Jiang

Collection Method

Likely contains a literature review or compiled research summary.

Freshness

Last updated 2026-04-27 05:16:33; freshness should be verified.